Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04521621
Recruitment Status : Active, not recruiting
First Posted : August 20, 2020
Last Update Posted : July 22, 2022
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

Tracking Information
First Submitted Date  ICMJE August 17, 2020
First Posted Date  ICMJE August 20, 2020
Last Update Posted Date July 22, 2022
Actual Study Start Date  ICMJE October 28, 2020
Estimated Primary Completion Date June 28, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 7, 2020)
  • Part 1: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    ORR is defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions and no new lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only the Part 1 arms will be analyzed in this outcome measure.
  • Number of Participants who Experience a Dose-Limiting Toxicity (DLT) [ Time Frame: Up to approximately 4 weeks ]
    DLTs are defined as toxicities that: are possibly, probably, or definitely related to study intervention administration; and meet pre-defined study criteria.
  • Part 2: Number of Participants Who Experienced One or More Adverse Events (AEs) [ Time Frame: Up to approximately 107 weeks ]
    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only the Part 2 arms will be analyzed in this outcome measure.
  • Part 2: Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE) [ Time Frame: Up to approximately 103 weeks ]
    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only the Part 2 arms will be analyzed in this outcome measure.
Original Primary Outcome Measures  ICMJE
 (submitted: August 17, 2020)
  • Arms A-C: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    ORR is defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions and no new lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only cohorts A-C will be analyzed in this outcome measure.
  • Number of Participants who Experience a Dose-Limiting Toxicity (DLT) [ Time Frame: Up to approximately 4 weeks ]
    DLTs are defined as toxicities that: are possibly, probably, or definitely related to study intervention administration; and meet pre-defined study criteria.
  • Cohorts D-H: Number of Participants Who Experienced One or More Adverse Events (AEs) [ Time Frame: Up to approximately 107 weeks ]
    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only cohorts D-H will be analyzed in this outcome measure.
  • Cohorts D-H: Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE) [ Time Frame: Up to approximately 103 weeks ]
    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only cohorts D-H will be analyzed in this outcome measure.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 7, 2020)
  • Part 1: Number of Participants Who Experienced One or More Adverse Events (AEs) [ Time Frame: Up to approximately 107 weeks ]
    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only the Part 1 arms will be analyzed in this outcome measure.
  • Part 1: Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE) [ Time Frame: Up to approximately 103 weeks ]
    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only the Part 1 arms will be analyzed in this outcome measure.
  • Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    PFS is defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by investigator. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only the Part 1 arms will be analyzed in this outcome measure.
  • Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    For participants who demonstrate a confirmed immune-based Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only the Part 1 arms will be analyzed in this outcome measure.
  • Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 for Immune-Based Therapeutics (iRECIST) as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    PFS is defined as the time from first dose of study treatment to the first documented immune-based confirmed progressive disease (iCPD) or death due to any cause, whichever occurs first as assessed by investigator. Per iRECIST, iCPD is defined as worsening of any existing cause of progression, or the appearance of any other cause of progression, relative to the initial appearance of progressive disease by RECIST 1.1. Only the Part 1 arms will be analyzed in this outcome measure.
  • Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors 1.1 for Immune-Based Therapeutics (iRECIST) as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    For participants who demonstrate a confirmed immune-based Complete Response (iCR: Disappearance of all target lesions) or an immune-based Partial Response (iPR: ≥30% decrease in the sum of diameters of target lesions) per iRECIST 1.1 as assessed by investigator, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only the Part 1 arms will be analyzed in this outcome measure.
  • Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 for Immune-Based Therapeutics (iRECIST) as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    ORR is defined as the percentage of participants in the analysis population who had an immune-based Complete Response (iCR: Disappearance of all target lesions) or an immune-based Partial Response (iPR: ≥30% decrease in the sum of diameters of target lesions) per iRECIST 1.1 as assessed by investigator.
  • Overall Survival (OS) [ Time Frame: Up to approximately 5 years ]
    OS is defined as the time from randomization to death due to any cause.
  • Solid Tumors+Liver Metastases Arms: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    ORR is defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions and no new lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only the Solid Tumors+Liver Metastases Dose Level 1-3 arms will be analyzed in this outcome measure.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 17, 2020)
  • Cohorts A-C: Number of Participants Who Experienced One or More Adverse Events (AEs) [ Time Frame: Up to approximately 107 weeks ]
    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only cohorts A-C will be analyzed in this outcome measure.
  • Cohorts A-C: Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE) [ Time Frame: Up to approximately 103 weeks ]
    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Only cohorts A-C will be analyzed in this outcome measure.
  • Cohorts A-C: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    PFS is defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by investigator. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only cohorts A-C will be analyzed in this outcome measure.
  • Cohorts A-C: Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    For participants who demonstrate a confirmed immune-based Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only cohorts A-C will be analyzed in this outcome measure.
  • Cohorts A-C: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 for Immune-Based Therapeutics (iRECIST) as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    PFS is defined as the time from first dose of study treatment to the first documented immune-based confirmed progressive disease (iCPD) or death due to any cause, whichever occurs first as assessed by investigator. Per iRECIST, iCPD is defined as worsening of any existing cause of progression, or the appearance of any other cause of progression, relative to the initial appearance of progressive disease by RECIST 1.1. Only cohorts A-C will be analyzed in this outcome measure.
  • Cohorts A-C: Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors 1.1 for Immune-Based Therapeutics (iRECIST) as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    For participants who demonstrate a confirmed immune-based Complete Response (iCR: Disappearance of all target lesions) or an immune-based Partial Response (iPR: ≥30% decrease in the sum of diameters of target lesions) per iRECIST 1.1 as assessed by investigator, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only cohorts A-C will be analyzed in this outcome measure.
  • Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 for Immune-Based Therapeutics (iRECIST) as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    ORR is defined as the percentage of participants in the analysis population who had an immune-based Complete Response (iCR: Disappearance of all target lesions) or an immune-based Partial Response (iPR: ≥30% decrease in the sum of diameters of target lesions) per iRECIST 1.1 as assessed by investigator.
  • Overall Survival (OS) [ Time Frame: Up to approximately 5 years ]
    OS is defined as the time from randomization to death due to any cause.
  • Cohorts D-F: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator [ Time Frame: Up to approximately 5 years ]
    ORR is defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions and no new lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and to specify that intratumoral injection does not render a lesion non-evaluable. Only cohorts D-F will be analyzed in this outcome measure.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
Official Title  ICMJE A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors
Brief Summary The purpose of this study is to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies who receive V937 in Combination with Pembrolizumab (MK-3475). The primary objective for Part 1 is to evaluate the objective response rate, and the primary objective for Part 2 is to determine the safety and tolerability of V937 administered in combination with pembrolizumab.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Neoplasm Metastasis
Intervention  ICMJE
  • Biological: V937
    Participants receive V937 intratumorally for 1 28-day cycle followed by 7 21-day cycles.
    Other Names:
    • Coxsackievirus A21 (CVA21)
    • Formerly known as CAVATAK®
    • CAV21
  • Drug: Pembrolizumab
    Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.
    Other Names:
    • MK-3475
    • KEYTRUDA®
Study Arms  ICMJE
  • Experimental: Part 1, Cohort A: Triple-Negative Breast Cancer
    This arm will enroll participants with triple-negative breast cancer (TNBC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
    Interventions:
    • Biological: V937
    • Drug: Pembrolizumab
  • Experimental: Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma
    This arm will enroll participants with head and neck squamous cell carcinoma (HNSCC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
    Interventions:
    • Biological: V937
    • Drug: Pembrolizumab
  • Experimental: Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma
    This arm will enroll participants with cutaneous squamous cell carcinoma (cSCC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
    Interventions:
    • Biological: V937
    • Drug: Pembrolizumab
  • Experimental: Part 2 Dose Level 1, Solid Tumors+Liver Metastases
    This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 1 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
    Interventions:
    • Biological: V937
    • Drug: Pembrolizumab
  • Experimental: Part 2 Dose Level 2, Solid Tumors+Liver Metastases
    This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 2 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
    Interventions:
    • Biological: V937
    • Drug: Pembrolizumab
  • Experimental: Part 2 Dose Level 3, Solid Tumors+Liver Metastases
    This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 3 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
    Interventions:
    • Biological: V937
    • Drug: Pembrolizumab
  • Experimental: Part 2, Cohort D: Hepatocellular Carcinoma (HCC)
    This arm will enroll participants with hepatocellular carcinoma (HCC) solid tumors. Participants receive the V937 recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
    Interventions:
    • Biological: V937
    • Drug: Pembrolizumab
  • Experimental: Part 2, Cohort E: Gastric Carcinoma
    This arm will enroll participants with gastric carcinoma solid tumors. Participants receive the V937 recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
    Interventions:
    • Biological: V937
    • Drug: Pembrolizumab
Publications * Deng JZ, Rustandi RR, Barbacci D, Swartz AR, Gulasarian A, Loughney JW. Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification. Hum Gene Ther. 2022 Jul;33(13-14):765-775. doi: 10.1089/hum.2022.013. Epub 2022 Jun 1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: August 17, 2020)
185
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 28, 2024
Estimated Primary Completion Date June 28, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Locally-advanced disease that is not amenable to surgery or radiation, or Stage IV advanced/metastatic solid tumor malignancies
  • Histologically- or cytologically-confirmed diagnosis of an advanced/metastatic solid tumor.
  • Measurable disease by RECIST 1.1 criteria as assessed by investigator. Target lesions in a previously irradiated area will be considered measurable if progression has been demonstrated in such lesions
  • Submitted a baseline tumor sample for analysis. Participants enrolling in Part 2 Cohorts D-F may enroll without submitting a tumor sample if all other enrollment criteria are met.
  • Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale obtained within 72 hours prior to the first dose of study intervention
  • If participant has known human immunodeficiency virus (HIV)-positive disease, participant must have well-controlled HIV on antiretroviral therapy (ART), per study criteria.
  • Adequate organ function
  • Male participants are eligible to participate if they agree to the following during the intervention period and for at least 120 days: Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR must agree to use contraception unless confirmed to be azoospermic.
  • Female participants are eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

    • Is not a woman of childbearing potential (WOCBP)
    • Is a WOCBP and using a contraceptive method that is highly effective, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention.
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Part 1, All Cohorts: participants must have at least one injectable lesion amenable to injection and/or biopsy.
  • Part 1, Cohort A:

    • Locally recurrent, inoperable OR metastatic breast cancer treated with at least 1 prior line of therapy in the metastatic setting with skin involvement and/or subcutaneous lesions or accessible lymph nodes amenable to local injection. An exception would be allowed for participants who are not eligible to receive chemotherapy.
    • Diagnosis of triple-negative breast cancer (estrogen receptor, progesterone receptor, and HER2-receptor negative status)
  • Part 1, Cohort B:

    • Histologically confirmed advanced or metastatic head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, and/or larynx considered incurable and/or treated with no more than 1 previous line of therapy
    • Tumors must be PD-L1+
    • Documentation of HPV status for oropharyngeal cancers. Other HNSCC subtypes may submit HPV testing, but is not required.
  • Part 1, Cohort C:

    • Histologically confirmed cutaneous squamous cell carcinoma (cSCC) as the primary site of malignancy
    • Recurrent/metastatic disease only: Has metastatic disease defined as disseminated disease distant from the initial/primary site of diagnosis and/or with a history of locally-recurrent disease previously treated with surgery and/or radiotherapy, which is now incurable
    • Locally-advanced disease only: Must be ineligible for surgical resection per study criteria, and must have received prior radiation therapy to the index site or deemed ineligible for radiation therapy
  • Part 2, Solid Tumors+Liver Metastases Dose Level 1-3 arms:

    • Histologically-confirmed advanced/metastatic solid tumor that has progressed on all treatment known to confer clinical benefit
    • Metastatic liver lesion(s) not exceeding one-third of the total liver volume AND a minimum of one injectable liver lesion
  • Part 2, Cohort D:

    • Advanced hepatocellular carcinoma (HCC) following progression on, or intolerance to, sorafenib or lenvatinib with no curative options
    • Diagnosis of HCC confirmed by radiology, histology, or cytology
    • Child-Pugh Class A score
    • If a participant has a history of hepatitis C virus (HCV) infection, then he/she must have been successfully treated for this condition
    • Controlled (treated) hepatitis B participants will be allowed if they meet protocol-specified criteria
    • Participants who are anti-hepatitis B core (HBc) positive, negative for hepatitis B surface antigen (HBsAg), negative or positive for anti-hepatitis B surface (HBs), and who have an HBV viral load under 100 IU/mL, do not require HBV anti-viral prophylaxis
  • Part 2, Cohort E:

    • Histologically- or cytologically-confirmed diagnosis of locally advanced, unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    • Received at least one prior line of therapy that includes a platinum/fluoropyrimidine doublet or triplet regimen
    • Had proven clinical progression 6 months following (or during) last dose of adjuvant or neo-adjuvant therapy
    • Human epidermal growth factor receptor 2 (HER2) negative status; or, those with HER2 positive status AND documented disease progression on a prior regimen containing trastuzumab

Exclusion Criteria:

  • Chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) prior to first dose of study intervention, or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better
  • If major or minor surgery was performed at/near the area being considered for injection, participant must be recovered from toxicity and/or complications of intervention
  • If participant has had injection or radiation therapy, participant must be recovered from toxicity and/or complications of intervention
  • History of second malignancy, unless potentially curative treatment has been completed with no further evidence of malignancy
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with treated brain metastases may participate if lesions are radiologically stable.
  • Active infection requiring therapy, except HIV criteria as stated above, and HBV and HCV criteria for HCC cohort as stated above
  • History of interstitial lung disease
  • History of noninfectious pneumonitis requiring active steroid therapy or ongoing pneumonitis
  • Active autoimmune disease that required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy
  • Known Hepatitis B or C infections or known to be positive for HBsAg/HBV deoxyribonucleic acid (DNA) or Hepatitis C Antibody or ribonucleic acid (RNA)
  • History of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known hypersensitivity to V937 and/or pembrolizumab or any of their excipients
  • Received prior therapy with anti-programmed cell death protein-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1) agents, Talimogene Laherparepvec (T-VEC), or any other oncolytic virus therapies
  • Received a live or live-attenuated vaccine within 30 days prior to first dose of study intervention. Administration of killed vaccines is allowed.
  • Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention
  • Part 2, Cohort D:

    • Has had esophageal or gastric variceal bleeding within the last 6 months
    • Has had clinically diagnosed hepatic encephalopathy in the 6 months prior to initiation of study intervention
  • Part 2, Cohort E:

    • Squamous cell or undifferentiated gastric cancer
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   France,   Germany,   Hungary,   Israel,   Italy,   Japan,   Norway,   Peru,   Poland,   Portugal,   Spain,   Taiwan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04521621
Other Study ID Numbers  ICMJE V937-013
V937-013 ( Other Identifier: Merck Protocol Number )
jRCT2033200191 ( Registry Identifier: jRCT )
2020-001908-42 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php
Current Responsible Party Merck Sharp & Dohme LLC
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Merck Sharp & Dohme LLC
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director Merck Sharp & Dohme LLC
PRS Account Merck Sharp & Dohme LLC
Verification Date July 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP